Literature DB >> 10452651

Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy.

W Tantisiriwat1, P Tebas, D B Clifford, W G Powderly, C J Fichtenbaum.   

Abstract

Recent reports suggest that human immunodeficiency virus (HIV)-associated progressive multifocal leukoencephalopathy (PML) may improve with highly active antiretroviral therapy (HAART). We observed three patients who developed PML while receiving HAART. All patients received HAART for 4-11 months and had low plasma levels of HIV-1 RNA before the onset of symptoms of PML. Antiretroviral therapy was changed in two patients, and their plasma HIV-1 RNA levels declined significantly. Despite this virologic response, PML did not improve in these patients. The third patient's HIV-1 RNA level became undetectable while he was receiving HAART, and his symptoms of PML improved after the addition of interferon alpha. Our observations suggest that PML can develop in patients who have shown clinical response to HAART. Furthermore, PML may not improve despite an adequate virologic response to HAART. Definitive therapy is still needed for PML.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452651     DOI: 10.1086/514762

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

1.  The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy.

Authors:  P Cinque; C Pierotti; M G Viganò; A Bestetti; C Fausti; D Bertelli; A Lazzarin
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

2.  The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS.

Authors:  M D Geschwind; R I Skolasky; W S Royal; J C McArthur
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

3.  Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?

Authors:  Renaud A Du Pasquier; Igor J Koralnik
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

Review 4.  The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature.

Authors:  Paola Cinque; Simona Bossolasco; Anna Maria Brambilla; Antonio Boschini; Cristina Mussini; Chiara Pierotti; Adriana Campi; Salvatore Casari; Davide Bertelli; Maurizio Mena; Adriano Lazzarin
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

Review 5.  Challenges for clinical trials to treat progressive multifocal leukoencephalopathy.

Authors:  David B Clifford
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

6.  Progressive Multifocal Leukoencephalopathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-07       Impact factor: 3.598

Review 7.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

8.  Case 15: when a stroke is not a stroke.

Authors:  W Bryan Burnette
Journal:  MedGenMed       Date:  2007-01-30

9.  Unmasking of PML by HAART: unusual clinical features and the role of IRIS.

Authors:  Navdeesh Sidhu; J Allen McCutchan
Journal:  J Neuroimmunol       Date:  2009-12-04       Impact factor: 3.478

10.  Spectrum of intracranial parenchymal lesions in patients with human immunodeficiency virus infection in the Republic of Korea.

Authors:  Pyoeng Gyun Choe; Wan Beom Park; Jin Su Song; Kyoung-Ho Song; Jae Hyun Jeon; Sang-Won Park; Hong Bin Kim; Kee-Hyun Chang; Myoung-don Oh; Kang Won Choe; Nam Joong Kim
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.